Partnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION DECEMBER 2016

Transcription

1 Partnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION DECEMBER 2016

2 Corporate Overview A unique source of therapeutic human antibodies with one of the industry's most versatile technology platforms, validated through two products in the clinic Pure partnered-discovery provider High-quality, high-value antibodies based on cutting-edge technology, that integrates antibody screening and optimization platforms Dual offering of natural and engineered libraries, providing both phage and yeast display options Only provider of rapid humanization of rabbit antibodies 2

3 What We Offer to Partners AbCheck s suite of antibody technologies: Human New: SuperHuman New: Mass Humanized AbSieve AbAccel Human Antibody Libraries Selection Optimization Provides partners with various options for the de novo discovery of antibodies against virtually all targets in scfv, IgG or bi-specific formats the optimization of existing antibody-based drug candidates 3

4 Our Current Partner Network - Over 30 Successful Antibody Discovery Projects Undisclosed partners 4

5 AbCheck s Commitment to Meeting Industry Demands Industry Needs Desire to work in final drug format Desire to use in vivo generated antibodies and humanize them consistently Desire to optimize drug-like properties of antibody candidates Desire for novel smartlyengineered library focusing on developability AbCheck s Solution AbSieve Mass Humanization AbAccel SuperHuman Library, AbAccel 5

6 AbCheck s Unique Offering Three genetically and conceptually distinct libraries allow for sequence exclusivity and availability 6

7 AbCheck s Unique Offering AbCheck can provide a seamless and smart transition between phage and yeast display selection strategies 7

8 Case Study: Opportunities in Advancing Therapeutic Areas New therapeutic approaches on the rise that use antibodies or fragments as components Technology platform is particularly well suited to deliver single-chain variable fragments as targeting elements Natural Human Library has delivered highly specific scfv with affinities in the single digit nanomolar range used in initial project Chimeric Antigen Receptor (CAR) 8

9 Case Study: Immune Checkpoints Antibodies targeting Immune Checkpoints are powerful immuno-activators and have shown impressive results in various cancer indications AbCheck has identified anti-checkpoint IgGs with in vivo activity using its AbSieve technology 9

10 AbCheck Corporate Background Leadership with substantial expertise in the biopharmaceutical industry Experience in discovery platforms from Affimed, Celltech, Cosmix, Fresenius, Pieris and Scil Technology AbCheck is a fully-owned subsidiary of Affimed (Nasdaq: AFMD) Validation through clinical TandAb programs AbCheck retains a maximum level of independence No shared labs or location 10

11 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE

12 Unique Antibody Sources, Selection Methods and Optimization Tools Human SuperHuman Mass Humanized AbSieve AbAccel Human Antibody Libraries Selection Optimization Unique sources of human antibodies through natural and smartly-engineered libraries Next generation Yeast Display capability Advanced optimization tools 12

13 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE - LIBRARIES

14 AbCheck s Antibody Libraries Use Three Distinct Sources of Diversity Human SuperHuman Mass Humanized Natural Engineered Immunized 14

15 The Human Antibody Library Low immunogenicity by nature Largest structural diversity Delivers high affinity and highly specific antibodies without optimizations From healthy donors (not engineered) Used by AbCheck since 2010 with proven and robust performance 15

16 New: The SuperHuman Library Engineered library based on proven drug scaffolds with ideal framework Largest heavy-chain CDR3 diversity Perfect match with AbAccel affinity maturation provides optimized CDR1/2 sequences Resulting in high-affinity antibodies with high stability and low immunogenicity Developed by Distributed Bio, in-licensed in

17 New: Mass Humanization Co-developed with Distributed Bio, AbCheck gained the exclusive license to the technology in 2015 A novel approach to human antibody discovery Combining the power of in vivo immunization with the best of in vitro engineering and in silico computational optimization Special potential for difficult targets Immunized libraries Computational design In vitro selection 17

18 AbCheck s Mass Humanization Delivers Antibodies That are More Human Other Companies Immunized rabbits Rabbit library / hybridomas Humanized library Lead candidate CDR graft Selected rabbit antibody VH VL Humanization of single antibodies VH VL 18

19 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE SELECTION IN THE FINAL DRUG FORMAT

20 AbSieve Next Generation Yeast Display for Advanced Selection Potential Recommended for selections of IgG and bi-specifics Screening in final drug format IgG (bivalent) Target specific VH/VL pools Yeast Display Bi-specific formats Any other formats AbSieve avoids drop-outs due to reformatting 20

21 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE OPTIMIZATION

22 AbAccel High-end Lead Optimization AbCheck has the exclusive license to the technology, co-developed with Distributed Bio Premium optimization method To meet special affinity requirements To improve developability Quality upgrade and final polishing before development Maintains beneficial antibody properties 22

23 AbAccel Optimizes Affinity While Preserving Other Drug-Relevant Properties AbAccel achieved two logs improvement of both: Binding to Human antigen Binding to Cyno antigen Preserving crossreactivity advantage for later tox studies Starting Clone Human KD (log 10 of nm) Preserving stability / same melting point range 23

24 AbCheck Summary One of the most versatile therapeutic antibody platforms that provides a customizable way to your lead candidate Accessible through a pure partnered-discovery model Experts in: antibody discovery lead optimization and humanization Successfully validated platform AbCheck antibodies already in clinical and preclinical development Seeking more partners for drug discovery and novel technology to add further capabilities 24

25 Contact: Thomas Waldmann, PhD MBA VP Business Development AbCheck

26 Partnered Discovery of High-quality Antibody Drug Candidates THANK YOU